Clinical Repository to Understand, Study, and Heal Myelodysplastic Syndrome |
Advances in MDS research
Dr. Sekeres discusses new advances in myelodysplastic syndrome research and treatment.
Your MDS Questions Answered
In 2004, Kirby Stone was diagnosed with myelodysplastic anemia syndrome, and was told he only had three months to put his affairs in order. Interested in arming themselves with as much information about the latest in myelodysplastic syndrome, Kirby and his wife Nancy attend the 2011 American Society of Hematology meeting to ask myelodysplastic syndrome specialist Dr. Sekeres about low-dose regimens, success rates of BMTs (bone marrow transplants) and how the future looks for patients with myelodysplastic syndrome.
MDS Classification Systems for Prognosis (parts 1 through 6)
Three physicians (Dr. Mikkael Sekeres, Dr. Hetty Carraway, and Dr. David Steensma) with extensive experience treating patients with myelodysplastic syndromes discuss the challenges in its diagnosis and management. The conversation covers classification and identification of low risk and high risk myelodysplastic syndrome, standard treatments, refractory myelodysplastic syndrome, and how they discuss treatment options with these patients and their caregivers.
| Video One | Video Two | Video Three | Video Four | Video Five | Video Six |
2014 Annual Hematology Meeting: MDS, ALL, & AML
In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. David P. Steensma review and discuss pertinent clinical trials and late breaking updates on therapeutic options and management strategies for patients with myelodysplastic syndrome, acute lymphocytic leukemia and acute myeloid leukemia. This engaging conversation provides comprehensive and easily accessible take home points for the practicing clinician.
ASH 2012: Myelodysplastic Syndrome with a Focus on Secondary MDS in CLL
Dr. Steensma discusses secondary myelodysplastic syndrome as it relates to chronic lymphocytic leukemia.
Iron Chelation Therapy for MDS
Dr. Steensma discusses the arguments against the use of iron chelation in patients with myelodysplastic syndrome.
Dr. Komrokji Discusses Myelodysplastic Syndromes
Dr. Komrokji discusses the risk factors for developing myelodysplastic syndromes (MDS).
What is New on the Horizon
Dr. Komrokji discusses new treatments on the horizon at the 2012 MDS Patient & Family Forum in Miami, Florida.
Approved Treatment for Intermediate and High Risk MDS
Dr. Desai discusses treatments available for intermediate and high risk myelodysplastic syndrome
What to Expect When You're Expecting MDS
Dr. Ritchie discusses what to expect during a diagnosis of myelodysplastic syndrome.
Clinical Trials 101
Dr. Roboz discusses the importance of people with myelodysplastic syndrome participating in clinical trials.
Translational Research: Don’t Throw Science in the Garbage
Dr. Roboz discusses the importance of translational scientific studies on the blood and bone marrow of people with myelodysplastic syndrome.
New Directions in MDS Treatment: What's on the Horizon?
Dr. Roboz discusses new treatments for myelodysplastic syndrome that are currently on the horizon.
MDS: Current Thinking on the Disease, Diagnosis, and Treatment
Dr. Roboz discusses the basics of myelodysplastic syndrome.
Molecular Mutations in MDS
Dr. Roboz discusses the growing field of molecular mutations in myelodysplastic syndromes.
